Aligos Therapeutics Presents Five Abstracts at The Liver Meeting® 2026
News related to:Aligos Therapeutics · 1 min read
SOUTH SAN FRANCISCO, Calif., Oct. 05, 2026 /CourierPR/ -- Aligos Therapeutics, a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, has announced that five abstracts have been accepted for presentation at The Liver Meeting® 2026, organized by the American Association for the Study of Liver Disease (AASLD). The conference, scheduled for November 5-9, 2026, in Denver, Colorado, will feature presentations on the company's latest advancements in treating hepatitis B virus (HBV) infection.
This presentation is scheduled for November 8, 2026, from 1:00 PM to 2:00 PM Mountain Time (MT) and will be part of the Hepatitis B session, which is designated as "4001-4193" and includes the "Poster of Distinction" category.
This presentation, led by Professor Man-Fung Yuen, Chair and Chief of the Division of Gastroenterology and Hepatology at the University of Hong Kong, will also take place from 1:00 PM to 2:00 PM MT and will be part of the same session.
This presentation will be part of the Hepatitis B session.
Aligos Therapeutics is also presenting an abstract on its potential best-in-class antisense oligonucleotide, ALG-170675, for chronic HBV infection. This presentation will also be part of the Hepatitis B session.
Lastly, the company will present an abstract on the potent inhibition of hepatitis delta virus replication by the antisense oligonucleotide ALG-215007. This preclinical study, presented by Kellan Passow, PhD, on November 7, 2026, from 1:00 PM to 2:00 PM MT, will be part of the "Hepatitis - Other Infections" session, which is designated as "3195-3246."
Aligos Therapeutics, founded with the mission to improve patient outcomes by developing best-in-class therapies for liver and viral diseases, continues to advance its pipeline of therapeutics for high unmet medical needs such as chronic hepatitis B virus infection. The company's research focuses on developing innovative treatments that can significantly impact the lives of patients suffering from these conditions.